Page 87 - SAHCS HIVMed Journal Vol 20 No 1 2019

Page 3 of 3 Case Report

Funding Information 4. Rossouw TM, Nieuwoudt M, Manasa J, et al. HIV drug resistance levels in adults
failing first line antiretroviral therapy in urban and rural settings in South Africa.
This work was financially supported by the National HIV Med. 2017;18(2):104–114. https://doi.org/10.1111/hiv.12400
Research Foundation (NRF) (grant number 87876) and the 5. Moyo S, Gaseitsiwe S, Powis KM, et al. Undisclosed antiretroviral drug use in
Botswana: Implication for national estimates. AIDS 2018;32(11):1543–1546.
University of Pretoria and National Health Laboratory https://doi.org/10.1097/QAD.0000000000001862
Service (NHLS) Research Trust (grant number 94447). 6. Kaplan SR, Oosthuizen C, Stinson K, et al. Contemporary disengagement
from antiretroviral therapy in Khayelitsha, South Africa: A cohort study.
PLoS Med. 2017;14(11):e1002407. https://doi.org/10.1371/journal.pmed.
1002407
Data availability statement 7. WHO, CDC, Global Fund. HIV drug resistance report 2017 [homepage on the
Internet]. Geneva: World Health Organization; 2017 [cited 2019 Feb 28]. Licence:
The clinical and genotypic data will be made available on CC BY-NC-SA 3.0 IGO. Available from: https://apps.who.int/iris/bitstream/
handle/10665/255896/9789241512831-eng.pdf?sequence=1
request.
8. Kantor R, Smeaton L, Vardhanabhuti S, et al. Pretreatment HIV drug resistance
and HIV-1 subtype care independently associated with virologic failure: Results
from the multinational PEARLS (ACTG A5175) clinical trial. Clin Infect Dis.
Disclaimer 2015;60(10):1541–1549. https://doi.org/10.1093/cid/civ102
9. Hamers RL, Schuurman R, Sigaloff KC, et al. Effect of pretreatment HIV-1 drug
The views expressed in the article are those of the authors resistance on immunological, virological, and drug-resistance outcomes of first-
and not an official position of the institution or funder. line antiretroviral treatment in sub-Saharan Africa: A multicentre cohort study.
Lancet Infect Dis. 2012;12(4):307–317. https://doi.org/10.1016/S1473-3099 (11)
70255-9
References 10. Parienti J-J, Massari V, Descamps D, et al. Predictors of virologic failure and
resistance in HIV-infected patients treated with nevirapine- or efavirenz-based
antiretroviral therapy. Clin Infect Dis [serial online]. 2004 [cited 2019
1. Manasa J, Katzenstein D, Cassol S, Newell ML, De Oliveira T, Southern Africa Mar 01];38(9):1311–1316. Available from: https://academic-oup-com.ez.sun.
Treatment And Resistance Network (SATuRN). Primary drug resistance in South ac.za/cid/article/38/9/1311/317940
Africa: Data from 10 years of surveys. AIDS Res Hum Retroviruses. 2012;28(6): 11. Oyugi JH, Byakika-Tusiime J, Ragland K, et al. Treatment interruptions predict
558–565. https://doi.org/10.1089/AID.2011.0284 resistance in HIV-positive individuals purchasing fixed-dose combination
2. Liu TF, Shafer RW. Web resources for HIV type 1 genotypic-resistance test interpretation. antiretroviral therapy in Kampala, Uganda. AIDS. 2007;21(8):965–971. https://
Clin Infect Dis. 2006;42(11):1608–1618. https://doi.org/10.1086/503914 doi.org/10.1097/QAD.0b013e32802e6bfa
3. Parikh UM, Barnas DC, Faruki H, Mellors JW. Antagonism between the HIV-1 12. Grimsrud A, Barnabas RV, Ehrenkranz P, Ford N. Evidence for scale up: The
reverse-transcriptase mutation K65R and thymidine-analogue mutations at the differentiated care research agenda. J Int AIDS Soc. 2017;20(Suppl 4):22024.
genomic level. J Infect Dis. 2006;194(5):651–660. https://doi.org/10.1086/505711 https://doi.org/10.7448/IAS.20.5.22024

http://www.sajhivmed.org.za 80 Open Access